OpGen Announces Closing of $3.38 Million Registered Direct Offering
October 03, 2022 16:20 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
October 03, 2022 07:30 ET
|
OpGen, Inc.
Prospective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samplesUrine samples have been collected from over 1,800 patients at 4 U.S. clinical trial...
OpGen Announces $3.38 Million Registered Direct Offering
September 30, 2022 08:38 ET
|
OpGen, Inc.
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
September 20, 2022 07:30 ET
|
OpGen, Inc.
FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs)Initial project focuses on...
OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global...
Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
August 31, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
August 25, 2022 07:30 ET
|
OpGen, Inc.
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunityServices at launch include rapid turnaround sequencing of clinical isolates,...
OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 16:15 ET
|
OpGen, Inc.
Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022Requested additional 180-day...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time
July 28, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
July 26, 2022 07:30 ET
|
OpGen, Inc.
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST)Ares plans to strategically expand...